AstraZeneca announces availability of saxa / dapa FDC in UK

UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news